The US FDA intends to adopt a more systematic approach to advice and data reviews on the blood pressure effects of new drugs that is modeled after its evaluation of pro-arrhythmic effects.
Norman Stockbridge, director of FDA’s Division of Cardiovascular and Renal Products, said the agency is looking to standardize its approach to evaluating pressor effect data much as it has done...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?